Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | EPOR | P19235 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9697569 | 0.90 | FOLH1 (0.51) | FOLH1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL5146905 | 0.83 | ALDH1A1 (0.51) | FOLH1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL10419871 | 0.83 | FOLH1 (0.53) | FOLH1ALDH1A1HTTMAPTRXFP1 | |
| SCHEMBL11165465 | 0.82 | ALDH1A1 (0.48) | FOLH1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL8051476 | 0.82 | FOLH1 (0.43) | FOLH1ALDH1A1 | |
| SCHEMBL9219335 | 0.81 | ALDH1A1 (0.53) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5421388 | 0.81 | ALDH1A1 (0.53) | FOLH1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL31422729 | 0.81 | ALDH1A1 (0.53) | FOLH1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2957718 | 0.80 | ALDH1A1 (0.51) | FOLH1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL10491537 | 0.79 | HTT (0.47) | FOLH1ALDH1A1HTTMAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1231919-B1 | Derivatives of 1-amino-1-(hetero)arylaminocarbonyl-6-hydroxyaminocarbonylhexane useful in the treatment of tumors | SLOAN KETTERING INST CANCER (US) | 2015-09-30 | — | — | EP | disclosed |
| US-7345174-B2 | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2007-01-11 | — | — | US | disclosed |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-01-11 | — | — | US | disclosed |
| US-20060241129-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2006-10-26 | — | — | US | disclosed |
| US-7126001-B2 | Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040002506-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-01-01 | — | — | US | disclosed |
| US-6511990-B1 | Selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241129-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | FOLH1 2487/4885ALDH1A1 367/4885HTT 3562/4885 |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | FOLH1 2487/4885ALDH1A1 367/4885HTT 3562/4885 |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | FOLH1 2487/4885ALDH1A1 367/4885HTT 3562/4885 |
| US-20040002506-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | FOLH1 2310/4885ALDH1A1 398/4885HTT 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.